Barrow Hanley Mewhinney & Strauss Adds $347M in GE HealthCare Technologies Inc. ($GEHC)
Key Points
- Barrow Hanley Mewhinney & Strauss changed its GE HealthCare Technologies Inc. ($GEHC) stake by 82.7% last quarter, boosting to 11,884,588 shares worth $766.67 million.
- Wall Street's consensus rating on $GEHC is Buy and an average price target of $79.72.
- $GEHC last traded around $64.51.
Barrow Hanley Mewhinney & Strauss increased its position in GE HealthCare Technologies Inc. ($GEHC) by 82.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,884,588 shares of GE HealthCare Technologies Inc. after buying 5,378,190 shares during the quarter. Barrow Hanley Mewhinney & Strauss's holdings in GE HealthCare Technologies Inc. were worth $766.67 million as of its most recent filing.
GE HealthCare Technologies Inc. ($GEHC) Stock
GE HealthCare Technologies Inc. Earnings
GE HealthCare Technologies Inc. Dividend
Analysts Set New Price Targets
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.